Back to top
more

Envista (NVST)

(Real Time Quote from BATS)

$21.13 USD

21.13
272,712

+0.03 (0.14%)

Updated Sep 17, 2025 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Align Technology (ALGN) Launches Professional Whitening System

by Zacks Equity Research

Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.

Zacks Equity Research

OPKO Health (OPK) Forms JV, Establishes Presence in China

by Zacks Equity Research

OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.

Zacks Equity Research

Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities

by Zacks Equity Research

Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.

Zacks Equity Research

Tandem Diabetes (TNDM) Rides on Innovation Despite Cost Woes

by Zacks Equity Research

Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 insulin pumps by both new and existing users is encouraging.

Zacks Equity Research

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.

Zacks Equity Research

Masimo (MASI) Launches SuperSensor, Boosts Product Profile

by Zacks Equity Research

Masimo's (MASI) launch of SuperSensor can help clinicians to continuously monitor patients through one comprehensive, convenient, noninvasive fingertip solution.

Zacks Equity Research

LabCorp (LH) Bolsters RA Testing by Adding Myriad's Vectra

by Zacks Equity Research

According to LabCorp (LH), Vectra and the related IP and other assets from Myriad Genetics' autoimmune business complement its prior business activity.

Zacks Equity Research

Here's Why You Should Invest in Charles River (CRL) Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Zacks Equity Research

LHC Group (LHCG) to Boost Nationwide Presence With New Buyout

by Zacks Equity Research

LHC Group's (LHCG) deal win enables the company to acquire home health, hospice and therapy assets in 22 states.

Zacks Equity Research

Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes

by Zacks Equity Research

Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.

Zacks Equity Research

Omnicell (OMCL) New Buyout Expands Patient Engagement Suite

by Zacks Equity Research

With the FDS Amplicare acquisition, Omnicell (OMCL) is expected to gain from several healthcare trends, banking on its offerings of digital technologies, SaaS solutions, and tech-enabled services.

Zacks Equity Research

NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone

by Zacks Equity Research

NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) For Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE) owing to new store growth and pandemic-induced increase in demand for the company's offerings.

Zacks Equity Research

Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

Zacks Equity Research

Teleflex (TFX) Real-World Data Outcome Supports UroLift System

by Zacks Equity Research

Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.

Kinjel Shah headshot

7 Low Price-to-Book Stocks to Buy in September

by Kinjel Shah

The P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

Zacks Equity Research

Syneos Health (SYNH) Enhances Clinical Trials With New Pact

by Zacks Equity Research

Syneos Health (SYNH) recent partnership develops a more patient-centric travel experience, advances diversity and inclusion in clinical research.

Zacks Equity Research

Quest Diagnostic (DGX) Raises View on COVID-19 Testing Surge

by Zacks Equity Research

Going by the current situation of daily increase in the coronavirus case count, Quest Diagnostics (DGX) expects COVID-19 molecular testing volumes to remain stronger through the rest of the year.

Zacks Equity Research

NVST vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NVST vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

SmileDirectClub (SDC) Struggles With New Markets, High Debt

by Zacks Equity Research

SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.

Zacks Equity Research

ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

by Zacks Equity Research

A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients

Zacks Equity Research

Thermo Fisher (TMO) Introduces Vanquish Neo UHPLC System

by Zacks Equity Research

Thermo Fisher's (TMO) Nano-Capillary and Micro-Flow LC Systems will benefit principal investigators, laboratories and proteomics researchers in academia, biopharma and contract research organizations.

Zacks Equity Research

Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform

by Zacks Equity Research

Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.

Zacks Equity Research

Here's Why You Should Invest in Integer Holdings (ITGR) Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain traction from portfolio management.